Rohto Pharmaceutical (4527) Fundamentals 2026 — P/E 15.7x, Revenue Analysis | SniperIQ
Rohto Pharmaceutical (4527) is a JP-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥537.8B, trading at ¥2380.00 on the JPX. This SniperIQ fundamentals page covers Rohto Pharmaceutical's valuation (P/E 15.7x, P/B 1.8x), profitability (net margin 10.0%), revenue (¥343.7B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Rohto Pharmaceutical's market cap?
Rohto Pharmaceutical (4527) has a market capitalization of approximately ¥537.8B, trading at ¥2380.00 on the JPX. Market cap moves with the live share price.
What is Rohto Pharmaceutical's P/E ratio?
Rohto Pharmaceutical's trailing twelve-month P/E ratio is 15.7x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Rohto Pharmaceutical?
Rohto Pharmaceutical runs a net profit margin of 10.0%, a gross margin of 55.5%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Rohto Pharmaceutical generate?
Rohto Pharmaceutical reported revenue of ¥343.7B for fiscal year 2026, with net income of ¥34.2B and earnings per share (EPS) of 151.56. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Rohto Pharmaceutical pay a dividend?
Rohto Pharmaceutical offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Rohto Pharmaceutical financially healthy?
Rohto Pharmaceutical carries a debt-to-equity ratio of 0.20x and a current ratio of 2.04x, with a market beta of -0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Rohto Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Rohto Pharmaceutical (4527) the key facts are: market cap ¥537.8B, P/E 15.7x, revenue ¥343.7B, 52-week range 2064-2703. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Rohto Pharmaceutical's full fundamentals live
Get Rohto Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.